A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J. Ullrich, Mark W. Kieran, David Viskochil et al.|Neuro-Oncology|2020Cited by 82
Recycling of the Epidermal Growth Factor Receptor Is Mediated by a Novel Form of the Clathrin Adaptor Protein Eps15Susan Chi, Mark A. McNiven|Journal of Biological Chemistry|2011Cited by 52
Recent progress and novel approaches to treating atypical teratoid rhabdoid tumorElizabeth Alva, Ashley Margol, Jeffrey Rubens et al.|Neoplasia|2023Cited by 36
PNOC014: Phase I Study of Tovorafenib for Children With Relapsed/Recurrent Low-Grade Gliomas and Other Mitogen Activated Protein Kinase Pathway–Activated TumorsKaren Wright, Sabine Mueller, Cassie Kline et al.|JCO oncology advances.|2026Cited by 0